These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9486389)

  • 1. Serum antibodies to HIV-1 are produced post-measles virus infection: evidence for cross-reactivity with HLA.
    Baskar PV; Collins GD; Dorsey-Cooper BA; Pyle RS; Nagel JE; Dwyer D; Dunston G; Johnson CE; Kendig N; Israel E; Nalin DR; Adler WH
    Clin Exp Immunol; 1998 Feb; 111(2):251-6. PubMed ID: 9486389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the recombinant chimera proteins, LacZ-Env and Gag-Env, for immunological studies on HIV-1 infection.
    Morimoto M; Saitoh A; Ueba N; Nakata A; Shinagawa H
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):971-8. PubMed ID: 7506555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement-mediated enhancement of HIV-1 neutralisation by anti-HLA antibodies derived from polytransfused patients.
    Wilfingseder D; Spruth M; Ammann CG; Döpper S; Speth C; Dierich MP; Stoiber H
    Int Arch Allergy Immunol; 2003 May; 131(1):62-72. PubMed ID: 12759492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivities of HIV-1 gag-derived peptides with antibodies of HIV-1-infected and uninfected humans.
    Haist S; März J; Wolf H; Modrow S
    AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1909-17. PubMed ID: 1489579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactivity with SIVmac in east African HIV-1-positive sera: evidence against double infection with HIV-1 and a SIVmac/HIV-2-like virus.
    Blomberg J; Klasse PJ; Pehrson C
    Intervirology; 1990; 31(5):276-84. PubMed ID: 1703133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chains induced by receipt of HIV-1-derived envelope vaccines.
    De Santis C; Robbioni P; Longhi R; Lopalco L; Siccardi AG; Beretta A; Roberts NJ
    J Infect Dis; 1993 Dec; 168(6):1396-403. PubMed ID: 8245524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.
    Lorin C; Delebecque F; Labrousse V; Da Silva L; Lemonnier F; Brahic M; Tangy F
    Vaccine; 2005 Aug; 23(36):4463-72. PubMed ID: 15993518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of antibodies reacting with HIV gag proteins occasionally found in the serum of non-infected subjects.
    Bürgisser P; Frei PC
    Clin Exp Immunol; 1991 Aug; 85(2):219-23. PubMed ID: 1713811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human monoclonal antibodies to HIV-1: cross-reactions with gag and env products.
    Pollock BJ; McKenzie AS; Kemp BE; McPhee DA; D'Apice AJ
    Clin Exp Immunol; 1989 Dec; 78(3):323-8. PubMed ID: 2482145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
    Krachmarov C; Pinter A; Honnen WJ; Gorny MK; Nyambi PN; Zolla-Pazner S; Kayman SC
    J Virol; 2005 Jan; 79(2):780-90. PubMed ID: 15613306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand.
    Chaiwarith R; Praparattanapan J; Nuket K; Kotarathitithum W; Supparatpinyo K
    BMC Infect Dis; 2016 Apr; 16():190. PubMed ID: 27138005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies.
    Luo L; Li Y; Cannon PM; Kim S; Kang CY
    Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10527-31. PubMed ID: 1438241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-env and anti-gag antibodies in subjects infected with the human immunodeficiency virus].
    Sanz del Forcallo FJ; García Delgado R; Ortiz Maslloréns F
    Rev Clin Esp; 1989 Dec; 185(9):443-7. PubMed ID: 2696006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses.
    Nyambi PN; Nkengasong J; Peeters M; Simon F; Eberle J; Janssens W; Fransen K; Willems B; Vereecken K; Heyndrickx L
    J Infect Dis; 1995 Nov; 172(5):1228-37. PubMed ID: 7594658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
    Ota A; Tanaka-Taya K; Ueda S
    Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in human immunodeficiency virus type 1 (HIV-1) anti-p24 reactivities in serum of HIV-1-infected and uninfected subjects: analysis of indeterminate western blot reactions.
    Povolotsky J; Gold JW; Chein N; Baron P; Armstrong D
    J Infect Dis; 1991 Feb; 163(2):247-51. PubMed ID: 1899100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody specificity for human immunodeficiency virus type 1 in serum and cerebrospinal fluid from patients with AIDS and AIDS-related complex.
    Willoughby PB; Midgett JS; Folds JD
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1031-7. PubMed ID: 2482809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of antibody assays for identifying and distinguishing recent from long-term HIV type 1 infection.
    Parekh BS; Pau CP; Kennedy MS; Dobbs TL; McDougal JS
    AIDS Res Hum Retroviruses; 2001 Jan; 17(2):137-46. PubMed ID: 11177393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum reactivity to HIV-1 accessory gene products distinguishes East African from West African HIV strains as infecting agent.
    Goudsmit J; Dekker JT; Boucher CA; Smit L; De Ronde A; Debouck C; Barin F
    AIDS Res Hum Retroviruses; 1989 Oct; 5(5):475-7. PubMed ID: 2590553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.